נולוג'יקס 250 מ"ג

País: Israel

Idioma: hebreu

Font: Ministry of Health

ingredients actius:

BELATACEPT 25 MG/ML

Disponible des:

BRISTOL-MYERS SQUIBB (ISRAEL) LIMITED

Codi ATC:

L04AA28

formulario farmacéutico:

POWDER FOR CONCENTRATE FOR INFUSION

Vía de administración:

I.V

Fabricat per:

BRISTOL-MYERS SQUIBB S.R.L, ITALY

Grupo terapéutico:

BELATACEPT

indicaciones terapéuticas:

Nulojix, in combination with corticosteroids and mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen

Data d'autorització:

2012-08-01